Jun 11, 2021
In this space, we spend a great deal of time talking about the methods some health economists use to measure health outcomes and the value of new treatments. For example, we’ve gone to some lengths to explain why analyses and valuations based on the quality...
May 14, 2021
In 2018, the UK’s National Institute for Health and Care Excellence (NICE) produced a valuation study that ultimately recommended that researchers replace the EQ-5D-3L quality of life measure with a modified instrument called the EQ-5D-5L. A lengthy debate ensued....
May 3, 2021
On April 16, 2021, the Institute for Clinical and Economic Review (ICER) released its final evidence report on two new treatments for lupus nephritis: Benlysta (manufactured by GlaxoSmithKline) and Lupkynis (Aurinia Pharmaceuticals). In the report, ICER claims to have...
Apr 23, 2021
After years of perpetually rising healthcare costs – not to mention a worldwide pandemic – many elected officials and policymakers – at both the state and federal level – are looking for ways to bring down the cost of public health programs. More and more often, these...
Apr 12, 2021
by Rick Gates, Rich Tremonte, & Robert Popovian The date when the U.S. Food and Drug Administration authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use, Dec. 11, 2020, was a seminal moment in human achievement. Never had a safe and effective vaccine...
Apr 12, 2021
By Robert Popovian and Wayne Winegarden The time has come for us to think about incremental, evolutionary, and targeted changes to the healthcare system to reduce costs rather than focusing on grand bargains. It is time for practical solutions that will likely have...
